We are a pioneering life sciences MLOps company for the future that transforms biological discovery by integrating different forms of biomedical data. We support discovery programs at Pfizer, Bristol Myers Squibb, Stanford and Yale and have 35+ research partners from premier biopharma companies and research labs. We are a 150+ multi-disciplinary team of experts based across the US, Canada, and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our old investors Hyperplane and IvyCap. We have developed Polly, an industry-leading data-centric MLOps platform for life sciences. Its technology cleans and links 26 types of biomedical data at scale into an ML-ready form. Polly delivers 70 TB of ML-ready biomedical data from ~30 different sources to customers. The platform helps data science teams to scale up by providing them with curated ML-ready biomolecular data from public and proprietary sources. Inspired by the FAIR guidelines described by the NIH, Polly's OmixAtlases allow exclusive access to curated multi-omics data that is ready for ML workflows. Polly offers 10x faster identification of therapeutic assets with high odds of success in the clinic. It has enabled the detection of multiple validated drug targets across immunology, oncology, and metabolic disorders. For more information, visit https://elucidata.io/ and follow us on https://twitter.com/elucidatacorp. Check out our GitHub to learn more about our code-first approach https://github.com/ElucidataInc/polly-python.